A pilot study to determine the safety and efficacy of monochromatic excimer light in the treatment of vitiligo

Stacy M. Chimento, Meggan Newland, Carlos Ricotti, Steven Nistico, Paolo Romanelli

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background and Objective: According to a European pilot study, the 308-nanometer (nm) Excilite μ™ (DEKA, Florence, Italy) system may be a promising tool for patients with vitiligo by offering targeted phototherapy, a rapid onset of repigmentation, and few adverse effects. The objective of this study was to evaluate the clinical efficacy and safety of the 308-nm Excilite μ in the treatment of vitiligo. Methods and Limitations: Ten patients with stable vitiligo were exposed to 10 weeks of targeted phototherapy with the Excilite μ device, followed by 5 weeks of observation. Skin types 1 and 2 were not included in the cohort, and Wood's light examination was not documented. Results: At 2 weeks, repigmentation was observed in 60% of the subjects, according to patient assessment, and 50% of the subjects, according to the treating physician and independent observer assessments. All patients maintained the repigmentation during the 5-week, follow-up period. Conclusion: The 308-nm Excilite μ is a safe and fast-acting therapeutic option in patients with stable vitiligo and skin types 3 through 6.

Original languageEnglish
Pages (from-to)258-263
Number of pages6
JournalJournal of Drugs in Dermatology
Volume7
Issue number3
StatePublished - Mar 1 2008

Fingerprint

Vitiligo
Safety
Light
Phototherapy
Therapeutics
Skin
Italy
Observation
Physicians
Equipment and Supplies

ASJC Scopus subject areas

  • Dermatology
  • Medicine(all)

Cite this

A pilot study to determine the safety and efficacy of monochromatic excimer light in the treatment of vitiligo. / Chimento, Stacy M.; Newland, Meggan; Ricotti, Carlos; Nistico, Steven; Romanelli, Paolo.

In: Journal of Drugs in Dermatology, Vol. 7, No. 3, 01.03.2008, p. 258-263.

Research output: Contribution to journalArticle

Chimento, Stacy M. ; Newland, Meggan ; Ricotti, Carlos ; Nistico, Steven ; Romanelli, Paolo. / A pilot study to determine the safety and efficacy of monochromatic excimer light in the treatment of vitiligo. In: Journal of Drugs in Dermatology. 2008 ; Vol. 7, No. 3. pp. 258-263.
@article{6a9b15b5876a41d89257e1917129f09e,
title = "A pilot study to determine the safety and efficacy of monochromatic excimer light in the treatment of vitiligo",
abstract = "Background and Objective: According to a European pilot study, the 308-nanometer (nm) Excilite μ™ (DEKA, Florence, Italy) system may be a promising tool for patients with vitiligo by offering targeted phototherapy, a rapid onset of repigmentation, and few adverse effects. The objective of this study was to evaluate the clinical efficacy and safety of the 308-nm Excilite μ in the treatment of vitiligo. Methods and Limitations: Ten patients with stable vitiligo were exposed to 10 weeks of targeted phototherapy with the Excilite μ device, followed by 5 weeks of observation. Skin types 1 and 2 were not included in the cohort, and Wood's light examination was not documented. Results: At 2 weeks, repigmentation was observed in 60{\%} of the subjects, according to patient assessment, and 50{\%} of the subjects, according to the treating physician and independent observer assessments. All patients maintained the repigmentation during the 5-week, follow-up period. Conclusion: The 308-nm Excilite μ is a safe and fast-acting therapeutic option in patients with stable vitiligo and skin types 3 through 6.",
author = "Chimento, {Stacy M.} and Meggan Newland and Carlos Ricotti and Steven Nistico and Paolo Romanelli",
year = "2008",
month = "3",
day = "1",
language = "English",
volume = "7",
pages = "258--263",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "3",

}

TY - JOUR

T1 - A pilot study to determine the safety and efficacy of monochromatic excimer light in the treatment of vitiligo

AU - Chimento, Stacy M.

AU - Newland, Meggan

AU - Ricotti, Carlos

AU - Nistico, Steven

AU - Romanelli, Paolo

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Background and Objective: According to a European pilot study, the 308-nanometer (nm) Excilite μ™ (DEKA, Florence, Italy) system may be a promising tool for patients with vitiligo by offering targeted phototherapy, a rapid onset of repigmentation, and few adverse effects. The objective of this study was to evaluate the clinical efficacy and safety of the 308-nm Excilite μ in the treatment of vitiligo. Methods and Limitations: Ten patients with stable vitiligo were exposed to 10 weeks of targeted phototherapy with the Excilite μ device, followed by 5 weeks of observation. Skin types 1 and 2 were not included in the cohort, and Wood's light examination was not documented. Results: At 2 weeks, repigmentation was observed in 60% of the subjects, according to patient assessment, and 50% of the subjects, according to the treating physician and independent observer assessments. All patients maintained the repigmentation during the 5-week, follow-up period. Conclusion: The 308-nm Excilite μ is a safe and fast-acting therapeutic option in patients with stable vitiligo and skin types 3 through 6.

AB - Background and Objective: According to a European pilot study, the 308-nanometer (nm) Excilite μ™ (DEKA, Florence, Italy) system may be a promising tool for patients with vitiligo by offering targeted phototherapy, a rapid onset of repigmentation, and few adverse effects. The objective of this study was to evaluate the clinical efficacy and safety of the 308-nm Excilite μ in the treatment of vitiligo. Methods and Limitations: Ten patients with stable vitiligo were exposed to 10 weeks of targeted phototherapy with the Excilite μ device, followed by 5 weeks of observation. Skin types 1 and 2 were not included in the cohort, and Wood's light examination was not documented. Results: At 2 weeks, repigmentation was observed in 60% of the subjects, according to patient assessment, and 50% of the subjects, according to the treating physician and independent observer assessments. All patients maintained the repigmentation during the 5-week, follow-up period. Conclusion: The 308-nm Excilite μ is a safe and fast-acting therapeutic option in patients with stable vitiligo and skin types 3 through 6.

UR - http://www.scopus.com/inward/record.url?scp=47249161205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249161205&partnerID=8YFLogxK

M3 - Article

C2 - 18380207

AN - SCOPUS:47249161205

VL - 7

SP - 258

EP - 263

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 3

ER -